Trial Profile
neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination With Anastrozole to Those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy With Abemaciclib in Combination With Anastrozole in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Anastrozole; Loperamide
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Pharmacodynamics
- Acronyms neoMONARCH
- Sponsors Eli Lilly and Company
- 01 Apr 2022 Results (n=222) of exploratory post hoc analysis assessing the impact of baseline BMI on KI67% changes, achievement of complete cell cycle arrest (CCCA), clinical, and radiological responses in patients included in the NEOMONARCH trial published in the Breast Cancer Research and Treatment
- 15 Oct 2019 Results assessing biological and clinical effetcs of abemaciclib alone or in combination with anastrozole were published in the Clinical Cancer Research
- 29 Nov 2018 According to an Eli Lilly media release, data from this study will be presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) (Dec 2018).